VC investment fund Simpact Ventures have invested €3 million in the medical technology startup Ligence.
In addition to Simpact Ventures, other backers in the funding round included Coinvest Capital, the European Innovation Council, Lemonade Stand (an Estonian venture capital firm), the NGL business angel syndicate, and private investor Rita Sakus.
This funding will drive Ligence’s expansion efforts as the company prepares for FDA clearance in early 2025, opening new opportunities to make high-quality cardiac diagnostics more accessible worldwide. Arnas Karužas, the head of Ligence, says that he views the attracted investment as a validation of the company’s strategic direction.
Ligence is one of the Lithuanian startups developing deep medical technologies, which in recent years has attracted external investments for the development of its solutions and business development.
Simpact is the first VC investment fund in Poland based on the Impact Investing idea. For 5 years, they have been successfully investing in startups that create innovative technologies that solve problems of the modern world.
The TGS Baltic team – Dalia Tamašauskaitė-Žilienė, Paulius Dabulskis, Violeta Mačiulytė, Augustė Linauskaitė, Viktorija Jančiūraitė, Renaldas Paškevičius, Meda Stankutė, and Inesa Grybova – advised Simpact Ventures on all legal matters.
